A 'non-invasive' test for Inflammatory Bowel Disease


Point of Care Testing - for Inflammatory Bowel Disease -
Capable of distinguishing between Ulcerative Colitis
and Crohn’s Disease


The Invention

Inflammatory bowel disease is a life-long relapsing and remitting inflammatory disorder primarily affecting the gastrointestinal tract. 

Invasive diagnostic investigations, specifically colonoscopy and histopathological evaluation, are the current standard for diagnosis.  

This invention provides a method ofdiagnosing or assessing inflammatory bowel disease including Crohn’s disease and Ulcerative Colitis using a set of six protein/peptide markers by comparing the level of one or more markers relative to a reference value for the one or more markers.


The technology is also capable of distinguishing between Ulcerative Colitis and Crohn’s disease and the severity of the condition.


Key Benefits

The development of a point of care diagnostic test would provide:

·      Non-invasive testing

·      Rapid test and results

·      Accurate diagnosis

·      Significant reduction in medical costs

·      Faster intervention - better treatment options

·   Better disease management


The Opportunity

 UNSW is seeking a commercial partner to licence and/or to work collaboratively with the inventor
Dr Valerie Wasinger in the development of this diagnostic test.



Click here for a Print version of this technoloy brief


For more information contact:

Dr Joe Brennan

Business Development Manager

NewSouth Innovations

Ref: 13_2780

T:   +61 2 9385 7729 l M: +61 450 469 492

E:   j.brennan@nsinnovations.com.au




Patent Information:
For Information, Contact:
Emma Elliott
Business Development Manager
NewSouth Innovations Pty Ltd
Reference ID: 13_2780
Valerie Wasinger
Rupert Leong
Drug Development
Inflammatory Diseases
Life Sciences
© 2024. All Rights Reserved. Powered by Inteum